Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 16 | 2023 | 108 | 1.950 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 13 | 2023 | 24 | 1.520 |
Why?
|
| Immunosuppressive Agents | 12 | 2023 | 140 | 0.890 |
Why?
|
| Natalizumab | 3 | 2019 | 21 | 0.680 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2020 | 94 | 0.660 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 2 | 2019 | 111 | 0.650 |
Why?
|
| Immunologic Factors | 2 | 2019 | 34 | 0.650 |
Why?
|
| Filgrastim | 1 | 2019 | 5 | 0.640 |
Why?
|
| JC Virus | 1 | 2019 | 97 | 0.580 |
Why?
|
| Immunoglobulin G | 6 | 2020 | 94 | 0.510 |
Why?
|
| Disease Progression | 4 | 2020 | 722 | 0.310 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 6 | 2009 | 117 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2019 | 1197 | 0.290 |
Why?
|
| Interferon Regulatory Factor-1 | 3 | 2011 | 10 | 0.270 |
Why?
|
| Adult | 22 | 2020 | 8172 | 0.260 |
Why?
|
| Aquaporin 4 | 2 | 2014 | 7 | 0.220 |
Why?
|
| Neuromyelitis Optica | 2 | 2014 | 7 | 0.220 |
Why?
|
| Central Nervous System Diseases | 1 | 2023 | 18 | 0.210 |
Why?
|
| Female | 24 | 2020 | 15818 | 0.200 |
Why?
|
| Humans | 31 | 2023 | 28548 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 4 | 2011 | 199 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 3 | 2011 | 68 | 0.190 |
Why?
|
| Male | 18 | 2020 | 15399 | 0.180 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2020 | 8 | 0.170 |
Why?
|
| Middle Aged | 19 | 2016 | 9320 | 0.160 |
Why?
|
| Gadolinium | 2 | 2016 | 9 | 0.150 |
Why?
|
| Double-Blind Method | 6 | 2016 | 433 | 0.140 |
Why?
|
| Treatment Outcome | 9 | 2023 | 3622 | 0.140 |
Why?
|
| Brain | 3 | 2019 | 1696 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2023 | 3615 | 0.130 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2016 | 13 | 0.130 |
Why?
|
| 4-Aminopyridine | 2 | 1991 | 5 | 0.120 |
Why?
|
| Transplantation Conditioning | 3 | 2006 | 43 | 0.120 |
Why?
|
| Muscular Diseases | 1 | 2014 | 18 | 0.120 |
Why?
|
| Spinal Cord Compression | 1 | 2014 | 24 | 0.110 |
Why?
|
| Quality of Life | 2 | 2013 | 659 | 0.110 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1863 | 0.110 |
Why?
|
| Cladribine | 2 | 2023 | 2 | 0.110 |
Why?
|
| Tablets | 2 | 2023 | 6 | 0.110 |
Why?
|
| Central Nervous System | 3 | 2023 | 59 | 0.100 |
Why?
|
| Decompression, Surgical | 1 | 2014 | 130 | 0.100 |
Why?
|
| Aquaporins | 1 | 2012 | 7 | 0.100 |
Why?
|
| Escherichia coli Proteins | 1 | 2012 | 11 | 0.100 |
Why?
|
| Autoimmune Diseases | 2 | 2006 | 48 | 0.100 |
Why?
|
| Demyelinating Diseases | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 2023 | 51 | 0.090 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2011 | 2 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2011 | 7 | 0.090 |
Why?
|
| Oligodendroglia | 1 | 2011 | 37 | 0.090 |
Why?
|
| Neuroglia | 1 | 2011 | 49 | 0.090 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 294 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 2103 | 0.090 |
Why?
|
| DNA | 1 | 2010 | 104 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 9 | 0.080 |
Why?
|
| Recurrence | 2 | 2023 | 322 | 0.080 |
Why?
|
| Disability Evaluation | 3 | 2009 | 291 | 0.080 |
Why?
|
| Neuroprotective Agents | 1 | 2009 | 55 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2011 | 447 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2010 | 164 | 0.080 |
Why?
|
| Animals | 6 | 2012 | 3814 | 0.070 |
Why?
|
| Mice | 4 | 2012 | 1467 | 0.070 |
Why?
|
| Injections, Subcutaneous | 2 | 2016 | 25 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 352 | 0.060 |
Why?
|
| Europe | 2 | 2014 | 66 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2003 | 2 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 206 | 0.050 |
Why?
|
| Adolescent | 3 | 2013 | 2322 | 0.050 |
Why?
|
| Rabbits | 2 | 2012 | 194 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2011 | 116 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2012 | 539 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2011 | 317 | 0.040 |
Why?
|
| Time Factors | 2 | 2014 | 1497 | 0.040 |
Why?
|
| Astrocytoma | 1 | 1999 | 20 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2016 | 1397 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2011 | 437 | 0.040 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1999 | 34 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 1999 | 108 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2009 | 177 | 0.040 |
Why?
|
| Spinal Cord | 1 | 1999 | 85 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2009 | 170 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2016 | 1942 | 0.040 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 99 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2016 | 1 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2016 | 8 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2016 | 10 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2016 | 15 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 16 | 0.030 |
Why?
|
| Safety | 1 | 2016 | 45 | 0.030 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 27 | 0.030 |
Why?
|
| Whole-Body Irradiation | 3 | 2003 | 13 | 0.030 |
Why?
|
| Muscle Fatigue | 1 | 1996 | 12 | 0.030 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 34 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2016 | 64 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2016 | 49 | 0.030 |
Why?
|
| Pneumonia | 1 | 2016 | 77 | 0.030 |
Why?
|
| Fatigue | 1 | 1996 | 64 | 0.030 |
Why?
|
| Combined Modality Therapy | 3 | 2003 | 308 | 0.030 |
Why?
|
| Antilymphocyte Serum | 2 | 2009 | 4 | 0.030 |
Why?
|
| Creatine Kinase | 1 | 2014 | 22 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 1996 | 732 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 180 | 0.030 |
Why?
|
| Structural Homology, Protein | 1 | 2012 | 5 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 166 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Cross Reactions | 1 | 2012 | 11 | 0.030 |
Why?
|
| Reference Values | 1 | 2013 | 201 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2012 | 67 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 160 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 199 | 0.020 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2010 | 264 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 215 | 0.020 |
Why?
|
| Aged | 2 | 2014 | 9343 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2011 | 6 | 0.020 |
Why?
|
| Placebos | 1 | 1991 | 71 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 140 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 57 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1996 | 1213 | 0.020 |
Why?
|
| Movement | 1 | 1991 | 118 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2011 | 228 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2010 | 14 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 364 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 676 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 90 | 0.020 |
Why?
|
| Plasma | 1 | 2010 | 19 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2010 | 48 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2010 | 59 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 57 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2010 | 59 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 100 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2010 | 81 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 85 | 0.020 |
Why?
|
| Inflammation | 1 | 2011 | 288 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2009 | 5 | 0.020 |
Why?
|
| Antirheumatic Agents | 1 | 2010 | 86 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2010 | 117 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 2009 | 13 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 70 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2010 | 178 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1998 | 8 | 0.020 |
Why?
|
| Antigens, CD34 | 2 | 1998 | 14 | 0.020 |
Why?
|
| Methylprednisolone | 2 | 1998 | 22 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 496 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 520 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 269 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 623 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 438 | 0.020 |
Why?
|
| Spinal Fusion | 1 | 2014 | 473 | 0.020 |
Why?
|
| Biomarkers | 1 | 2010 | 601 | 0.020 |
Why?
|
| Factor VIII | 1 | 2006 | 32 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 990 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2003 | 163 | 0.010 |
Why?
|
| Radiography, Interventional | 1 | 1999 | 23 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1998 | 5 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 1998 | 15 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 1999 | 54 | 0.010 |
Why?
|
| Torque | 1 | 1996 | 28 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 1996 | 53 | 0.010 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 1998 | 192 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1998 | 612 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1996 | 599 | 0.010 |
Why?
|
| Vision Disorders | 1 | 1990 | 22 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1990 | 111 | 0.010 |
Why?
|
| Reaction Time | 1 | 1990 | 114 | 0.010 |
Why?
|